Armata Pharmaceuticals In... (ARMP)
2.02
0.00 (0.00%)
At close: Jan 14, 2025, 2:09 PM
2.02
0.00%
After-hours Jan 14, 2025, 08:00 PM EST
undefined% (undefined)
| Bid | 1.75 |
| Market Cap | 72.91M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.15 |
| PE Ratio (ttm) | -1.75 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.22 |
| Volume | 2,856 |
| Avg. Volume (20D) | 11,027 |
| Open | 2.05 |
| Previous Close | 2.02 |
| Day's Range | 1.98 - 2.07 |
| 52-Week Range | 1.80 - 4.48 |
| Beta | undefined |
About ARMP
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It h...
Industry Biotechnology
Sector Healthcare
IPO Date May 20, 1994
Employees 66
Stock Exchange AMEX
Ticker Symbol ARMP
Website https://www.armatapharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ARMP stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 247.39% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Armata Pharmaceuticals Inc. is scheduled to release its earnings on Mar 20, 2025,
during market hours.
Analysts project revenue of $1.56M, reflecting a 2.09% YoY growth and earnings per share of -0.35, making a -36.36% decrease YoY.
Analysts project revenue of $1.56M, reflecting a 2.09% YoY growth and earnings per share of -0.35, making a -36.36% decrease YoY.
